|
|
5301 Patrick Henry Drive
Santa Clara, CA 95054 USA
phone:408.200.9500
fax:(408) 215-2835
|
|
| Symbol |
Private |
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.ilypsa.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Non-absorbed, GI based drugs for renal and metabolic diseases |
|
| Management |
| Jay P. Shepard, President and Chief Executive Officer; Detlef Albrecht, M.D., Senior Vice President of R&D and Chief Medical Officer; Gerrit Klaerner, Ph.D., Senior Vice President, Chief Business Officer; William D. Waddill, Senior Vice President, Chief Financial Officer; Paul A. Stone, J.D, Senior Vice President, General Counsel and Chief Patent Counsel; Michael Burdick, Vice President, Regulatory Affairs and Quality Assurance; Jerry M. Buysse, Ph.D., Vice President, Preclinical Research and Development; Dominique Charmot, Ph.D., Vice President, Discovery and Chemistry; George Tyson, Vice President, Pharmaceutical Sciences |
| |
|
|
| |
|
| Keywords |
| non-absorbed, GI based, renal, metabolic, polymer, degradation, gastrointestinal tract |
|
|
|
| Description |
|
Ilypsa, Inc. is focused on non-absorbed, GI based drugs for renal and metabolic diseases utilizing a proprietary high throughput discovery and development platform created and validated at Symyx Technologies. |
|
| Products / Services |
Ilypsa's current drug candidates are based on tailored non-absorbed
polymers, where the polymer itself provides the drug function. By preventing degradation and systemic uptake, the polymeric drugs are designed to act in the gastrointestinal tract and clear the human body through the digestive system. The non-absorbed feature significantly simplifies toxicology and pharmacology requirements for this class of drugs, leading to superior safety and risk profiles.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members